Tools
Tools
Selvakumar, SC, Preethi, KA, Ross-Houle, K, Tusubira, D, Khan, MWA, Mani, P, Rao, TN and Sekar, D (2022) CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer, 21 (1). ISSN 1476-4598
|
Text
CRISPR Cas9 and next generation sequencing in the personalized treatment of Cancer.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Background: Cancer is caused by a combination of genetic and epigenetic abnormalities. Current cancer therapies are limited due to the complexity of their mechanism, underlining the need for alternative therapeutic approaches. Interestingly, combining the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) system with next-generation sequencing (NGS) has the potential to speed up the identification, validation, and targeting of high-value targets.
Main text: Personalized or precision medicine combines genetic information with phenotypic and environmental characteristics to produce healthcare tailored to the individual and eliminates the constraints of “one-size-fits-all” therapy. Precision medicine is now possible thanks to cancer genome sequencing. Having advantages over limited sample requirements and the recent development of biomarkers have made the use of NGS a major leap in personalized medicine. Tumor and cell-free DNA profiling using NGS, proteome and RNA analyses, and a better understanding of immunological systems, are all helping to improve cancer treatment choices. Finally, direct targeting of tumor genes in cancer cells with CRISPR/Cas9 may be achievable, allowing for eliminating genetic changes that lead to tumor growth and metastatic capability.
Conclusion: With NGS and CRISPR/Cas9, the goal is no longer to match the treatment for the diagnosed tumor but rather to build a treatment method that fits the tumor exactly. Hence, in this review, we have discussed the potential role of CRISPR/Cas9 and NGS in advancing personalized medicine.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | 1112 Oncology and Carcinogenesis |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Springer |
| Date Deposited: | 31 Mar 2022 09:54 |
| Last Modified: | 31 Mar 2022 10:00 |
| DOI or ID number: | 10.1186/s12943-022-01565-1 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/16565 |
 |
View Item |